JP2004504063A - 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 - Google Patents

新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 Download PDF

Info

Publication number
JP2004504063A
JP2004504063A JP2002514175A JP2002514175A JP2004504063A JP 2004504063 A JP2004504063 A JP 2004504063A JP 2002514175 A JP2002514175 A JP 2002514175A JP 2002514175 A JP2002514175 A JP 2002514175A JP 2004504063 A JP2004504063 A JP 2004504063A
Authority
JP
Japan
Prior art keywords
fgf23
nucleic acid
polypeptide
mammal
hypophosphatemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002514175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504063A5 (enExample
Inventor
エコンス，マイケル
ホワイト，ケン
ストロマ，ティム，マティアス
メイティンゲル，トーマス
Original Assignee
アドバンスド　リサーチ　＆　テクノロジー　インスティテュート
ルードヴィッヒ−マクシミリアンス−ユニベルシタット　ミュンヘン　アブテイラング　メディジニッシェ　ジェネティック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004504063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アドバンスド　リサーチ　＆　テクノロジー　インスティテュート, ルードヴィッヒ−マクシミリアンス−ユニベルシタット　ミュンヘン　アブテイラング　メディジニッシェ　ジェネティック filed Critical アドバンスド　リサーチ　＆　テクノロジー　インスティテュート
Publication of JP2004504063A publication Critical patent/JP2004504063A/ja
Publication of JP2004504063A5 publication Critical patent/JP2004504063A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
JP2002514175A 2000-07-19 2001-07-10 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 Pending JP2004504063A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21913700P 2000-07-19 2000-07-19
PCT/US2001/021738 WO2002008271A1 (en) 2000-07-19 2001-07-10 Novel fibroblast growth factor (fgf23) and methods for use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008025528A Division JP2008194039A (ja) 2000-07-19 2008-02-05 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法

Publications (2)

Publication Number Publication Date
JP2004504063A true JP2004504063A (ja) 2004-02-12
JP2004504063A5 JP2004504063A5 (enExample) 2008-03-27

Family

ID=22818027

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002514175A Pending JP2004504063A (ja) 2000-07-19 2001-07-10 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
JP2008025528A Pending JP2008194039A (ja) 2000-07-19 2008-02-05 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008025528A Pending JP2008194039A (ja) 2000-07-19 2008-02-05 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法

Country Status (11)

Country Link
US (5) US7223563B2 (enExample)
EP (2) EP2184296A1 (enExample)
JP (2) JP2004504063A (enExample)
KR (2) KR20090036151A (enExample)
CN (1) CN1446227B (enExample)
AT (1) ATE461213T1 (enExample)
AU (2) AU7332301A (enExample)
CA (1) CA2418215A1 (enExample)
DE (1) DE60141582D1 (enExample)
ES (1) ES2340662T3 (enExample)
WO (1) WO2002008271A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003057733A1 (ja) * 2001-12-28 2005-05-19 麒麟麦酒株式会社 線維芽細胞増殖因子−２３に対する抗体
JP2013517781A (ja) * 2010-01-29 2013-05-20 ノバルティス アーゲー Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物
KR20130137618A (ko) 2010-08-31 2013-12-17 교와 메덱스 가부시키가이샤 섬유아세포 증식 인자-２３ 의 측정 방법 및 측정 시약
JP2017524656A (ja) * 2014-06-09 2017-08-31 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． 最適な骨形成のための血清リンの効果的かつ効率的な制御
WO2018221544A1 (ja) 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
JP2022527790A (ja) * 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
CN101275136A (zh) * 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
RU2003123108A (ru) * 2000-12-26 2005-02-27 Чугаи Сейяку Кабусики Кайся (Jp) Мутантные формы человеческого белка fgf23, снижающие содержание фосфора в крови
WO2002088358A2 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
ATE507296T1 (de) * 2003-11-07 2011-05-15 Novartis Ag Verwendung von fibroblasten-wachstumsfaktor- fragmenten
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
EP1745151B1 (en) * 2004-05-09 2009-12-02 Technion Research And Development Foundation, Ltd. Methods relating to disorders associated with abnormal phosphate metabolism
MX2007013005A (es) * 2005-04-18 2008-01-16 Clearplay Inc Aparato, sistema y metodo para asociar uno o mas archivos de filtro con una presentacion multimedia particular.
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US8012694B2 (en) 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
WO2008089936A1 (en) * 2007-01-22 2008-07-31 Medizinische Universität Innsbruck Novel markers for chronic kidney disease
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
CN111269874B (zh) * 2013-09-20 2024-04-26 隆萨有限公司 细胞的核重编程的方法
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA2969307A1 (en) 2014-12-04 2016-06-09 Novartis Ag Methods and compositions using klotho variant polypeptides
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
WO2016210350A1 (en) 2015-06-25 2016-12-29 Amyris, Inc. Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3604503B1 (en) * 2017-03-28 2026-03-18 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
WO2020047475A1 (en) * 2018-08-30 2020-03-05 The Uab Research Foundation Drug screening for fgf23-fgfr4 inhibitors
EP3956354A1 (en) * 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
KR102987382B1 (ko) * 2020-11-27 2026-07-03 한국해양과학기술원 Fgf11 동형2 폴리펩타이드 및 그 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2391455A1 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
EP1246843A1 (en) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
EP1255771A4 (en) 2000-02-14 2004-09-29 Smithkline Beecham Corp NEW COMPOUNDS
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002076467A1 (en) * 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003057733A1 (ja) * 2001-12-28 2005-05-19 麒麟麦酒株式会社 線維芽細胞増殖因子−２３に対する抗体
JP4527982B2 (ja) * 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
JP2013517781A (ja) * 2010-01-29 2013-05-20 ノバルティス アーゲー Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物
EP3578979A1 (en) 2010-08-31 2019-12-11 Hitachi Chemical Diagnostics Systems Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
EP3985393A1 (en) 2010-08-31 2022-04-20 Minaris Medical Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
US12092637B2 (en) 2010-08-31 2024-09-17 Hitachi Chemical Diagnostics Systems Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
EP3101423A1 (en) 2010-08-31 2016-12-07 Kyowa Medex Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
US10422796B2 (en) 2010-08-31 2019-09-24 Kyowa Medex Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
KR20130137618A (ko) 2010-08-31 2013-12-17 교와 메덱스 가부시키가이샤 섬유아세포 증식 인자-２３ 의 측정 방법 및 측정 시약
US10639360B2 (en) 2014-06-09 2020-05-05 Ultragenyx Pharmaceutical, Inc. Methods for treating hypophosphatemic disorders
JP2021050226A (ja) * 2014-06-09 2021-04-01 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． 最適な骨形成のための血清リンの効果的かつ効率的な制御
US11202822B2 (en) 2014-06-09 2021-12-21 Ultragenyx Pharmaceutical Inc. Methods for treating hypophosphatemic disorders
JP6993490B2 (ja) 2014-06-09 2022-02-03 ウルトラジェニクス ファーマシューティカル インク． 最適な骨形成のための血清リンの効果的かつ効率的な制御
JP2017524656A (ja) * 2014-06-09 2017-08-31 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． 最適な骨形成のための血清リンの効果的かつ効率的な制御
US12358976B2 (en) 2014-06-09 2025-07-15 Ultragenyx Pharmaceutical Inc. Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
WO2018221544A1 (ja) 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
US12498366B2 (en) 2017-05-31 2025-12-16 Canon Medical Diagnostics Corporation Measurement method for fibroblast growth factor-23 by forming immunocomplexes
JP2022527790A (ja) * 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子

Also Published As

Publication number Publication date
CN1446227A (zh) 2003-10-01
US8586317B2 (en) 2013-11-19
US7745406B2 (en) 2010-06-29
US20020156001A1 (en) 2002-10-24
EP1303536A4 (en) 2005-01-05
US20080241946A1 (en) 2008-10-02
DE60141582D1 (de) 2010-04-29
AU7332301A (en) 2002-02-05
WO2002008271A1 (en) 2002-01-31
US20090311792A1 (en) 2009-12-17
US20120064544A1 (en) 2012-03-15
KR20030029111A (ko) 2003-04-11
EP1303536B1 (en) 2010-03-17
ATE461213T1 (de) 2010-04-15
JP2008194039A (ja) 2008-08-28
EP2184296A1 (en) 2010-05-12
AU2001273323B2 (en) 2005-11-10
US7314618B2 (en) 2008-01-01
CA2418215A1 (en) 2002-01-31
EP1303536A1 (en) 2003-04-23
US7947810B2 (en) 2011-05-24
US20030181379A1 (en) 2003-09-25
KR100924183B1 (ko) 2009-10-28
CN1446227B (zh) 2011-10-05
US7223563B2 (en) 2007-05-29
ES2340662T3 (es) 2010-06-08
KR20090036151A (ko) 2009-04-13

Similar Documents

Publication Publication Date Title
US7947810B2 (en) Kits for diagnosing a hypophosphatemic disorder
AU2001273323A1 (en) Novel fibroblast growth factor (FGF23) and methods for use
JPH08504577A (ja) ＴＧＦ−βの制御活性を改変するための組成物および方法
JP2002506625A (ja) サイトカインレセプター共通γ鎖様
US7404952B2 (en) Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
US20050049212A1 (en) Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
WO1998040487A1 (en) Angiogenin receptor, compositions and methods related thereto
JP2004514404A (ja) 血管形成関連タンパク質及びこれをコードする核酸
US20040242515A1 (en) Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
AU7841800A (en) Novel hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
US20050176659A1 (en) Endophilin homologous proteins involved in the regulation of energy homeostasis
US20050054822A1 (en) Hin-2 nucleic acid molecules, proteins, antibodies, homologues, receptors, and uses thereof
AU2002308110A1 (en) Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
WO2004050007A2 (en) Mammalian bt-42 proteins involved in the regulation of energy homeostasis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080205

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080205

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118